Relmada Therapeutics to Provide Corporate Update at 2015 Biotech Showcase™ in San Francisco

Presentation on January 13, 2015 at 11:00 AM Pacific Time.

NEW YORK, Jan. 6, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has been selected to present at the 7th Annual Biotech Showcase™ Conference at 11:00 AM Pacific Time (2:00 PM Eastern Time) on Tuesday, January 13, 2015. The presentation will take place in the D – Powell (3rd Floor) track at the Parc 55 Wyndham Hotel in San Francisco.

Sergio Traversa, Chief Executive Officer of Relmada Therapeutics, will provide an overview of the company and recent activities, including the ongoing human clinical trial with d-Methadone, the company's N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain.

A live audio webcast of the presentation will be available under the investor relations section of Relmada's website at A replay of the presentation will be available for 30 days following the event. Please connect to Relmada's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain.  The Company has a diversified portfolio of four lead products at various stages of development including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-Methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine.  The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.  For more information, please visit Relmada's website at:

Forward-Looking Statements

This news release contains "forward-looking statements."  These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements.  The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected.  Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 212-702-7169

To view the original version on PR Newswire, visit:

SOURCE Relmada Therapeutics, Inc.